26 May 2026

MAYER BROWN ADVISES SERB PHARMACEUTICALS ON THE AGREEMENT ENTERED INTO WITH HANSA BIOPHARMA AB TO ACQUIRE EUROPEAN AND MENA RIGHTS TO IDEFIRIX®(IMLIFIDASE)

Advising firms

3 lawyers named

The named deal team is included with full access

Full access shows the lawyers on every deal team, disclosed values, clients and counterparties.

Deal value, client and counterparties are included with full access

Full access shows the disclosed value and what it refers to, the client and every counterparty.